Angelica Thornton talked with cystic fibrosis patient Chloe and her doctor Michael Powers at OHSU.

The National Institute for Occupational Safety and Health awards $6.9 million to the Oregon Healthy Workforce Center at OHSU. This grant renews a five-year grant aimed to expand research into health care worker burnout and well-being, firefighter work schedules and chronic pain among home care workers.

“With any kind of new therapy being used on the human body for the first time, you always have to be cautious,” said Mark Pennesi, an ophthalmologist at the Casey Eye Institute at the Oregon Health & Science University who led the experiment. “There's the things you might know, and then there are the things you don't know. You have to always take a cautious approach.”

In a statement, OHSU pulls sponsorship, saying it's doing everything it can to avoid adding to its hospitals' burden.

OHSU patient files legal complaint filed alleging disability discrimination.

The data, including preliminary patient safety and efficacy assessments relating to potential clinical benefits, are being presented today in an oral presentation at the XIXth International Symposium on Retinal Degeneration (RD2021) by OHSU's Dr. Mark Pennesi, M.D., Ph.D.

A clinical trial evaluating a CRISPR-based gene editing technology to remove gene mutations that cause a form of blindness sees success. OHSU's Mark Pennesi, M.D., Ph.D., describes how two trial participants have experienced improved eyesight, including OHSU participant Carlene Knight who says she can now see more clearly.

“I am encouraged by these initial results, which indicate this investigational gene editing treatment has been well-tolerated in this trial’s participants thus far and may also help improve sight for people with mutations in the CEP290 gene,” stated Mark Pennesi, MD, PhD, of Oregon Health & Science University, where he is a Professor of Molecular and Medical Genetics, Kenneth C. Swan Endowed Professor of Ophthalmology, and Paul H. Casey Ophthalmic Genetics Division Chief for OHSU’s Casey Eye Institute.

OHSU's Mark Pennesi, M.D., Ph.D., describes how two trial participants have experienced improved eyesight, including OHSU participant Carlene Knight who says she can now see more clearly.

In coverage of initial results for a clinical trial evaluating a CRISPR-based gene editing technology to remove gene mutations that cause a form of blindness, OHSU's Mark Pennesi, M.D., Ph.D., describes how two trial participants have experienced improved eyesight, including OHSU participant Carlene Knight who says she can now see more clearly.